Zilong Li
Zilong Li
2Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Disease, Department of Pathophysiology, Nanjing Medical University, Nanjing, China
3Institute of Biomedical Research, Liaocheng University, Liaocheng, China
2,3,†,
Yuanyuan Zhang
Yuanyuan Zhang
2Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Disease, Department of Pathophysiology, Nanjing Medical University, Nanjing, China
4Department of Cardiovascular Medicine, Affiliated Hospital of Hainan Medical University, Haikou, China
2,4,†,
Yangxi Zhang
Yangxi Zhang
2Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Disease, Department of Pathophysiology, Nanjing Medical University, Nanjing, China
2,†,
Liming Yu
Liming Yu
2Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Disease, Department of Pathophysiology, Nanjing Medical University, Nanjing, China
2,†,
Bin Xiao
Bin Xiao
1Pancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
1,*,
Tianfa Li
Tianfa Li
2Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Disease, Department of Pathophysiology, Nanjing Medical University, Nanjing, China
4Department of Cardiovascular Medicine, Affiliated Hospital of Hainan Medical University, Haikou, China
2,4,*,
Xiaocen Kong
Xiaocen Kong
5Department of Endocrinology, Nanjing First Hospital, Nanjing Medial University, Nanjing, China
5,*,
Yong Xu
Yong Xu
2Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Disease, Department of Pathophysiology, Nanjing Medical University, Nanjing, China
3Institute of Biomedical Research, Liaocheng University, Liaocheng, China
2,3
1Pancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Disease, Department of Pathophysiology, Nanjing Medical University, Nanjing, China
3Institute of Biomedical Research, Liaocheng University, Liaocheng, China
4Department of Cardiovascular Medicine, Affiliated Hospital of Hainan Medical University, Haikou, China
5Department of Endocrinology, Nanjing First Hospital, Nanjing Medial University, Nanjing, China
✉*Correspondence: Bin Xiao xiaobin@jsph.org.cn
*Tianfa Li litf79997@aliyun.com
*Xiaocen Kong kongxiaocen2010@163.com
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
This article was submitted to Molecular Medicine, a section of the journal Frontiers in Cell and Developmental Biology
†These authors have contributed equally to this work
Received 2021 Jan 6; Accepted 2021 Jan 7; Collection date 2021.
Keywords: transcriptional regulation, macrophage infiltration, endothelial cell, Angiotensin II, cardiac hypertrophy
Copyright © 2021 Li, Zhang, Zhang, Yu, Xiao, Li, Kong and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PDF (82.4 KB)
